Pré-Eclâmpsia Grave. Compromisso Materno e Fetal

Introdução: A pré-eclâmpsia (PE) é uma síndrome específica da gravidez, associado a morbimortalidade materna e perinatal. Métodos: Estudo retrospectivo descritivo das 134 gestações com PE grave, seguidas na nossa instituição de 2003 a 2005, com o objectivo de avaliar as repercussões maternas e fetais desta patologia. Resultados: Na maioria dos casos houve repercussão sistémica, manifestada por sintomatogia (79%) e valores laboratoriais indicativos de gravidade clínica. Os dados ecográficos revelaram 22,7% de restrição de crescimento intra-uterino e 21,3% de fluxometria doppler patológica. Decidiu-se interromper electivamente a gravidez em 95,3% dos casos, 60,5% nas primeiras 48h, sendo a síndrome materno a principal indicação. Verificaram-se 4 abortos e 5 mortes fetais. O parto ocorreu antes das 34 semanas em 63,1% dos casos. Em 82,8% a via de parto foi cesariana. Salientam-se 4 casos de insuficiência renal aguda e 2 casos de acidente vascular cerebral hemorrágico com morte materna. 20% dos recém-nascidos eram leves para a idade gestacional e verificou-se asfixia neonatal em 7,7%. Conclusão: A pré-eclâmpsia grave continua a ser uma patologia com implicações importantes no desfecho obstétrico.

Treatment of Hepatitis C Virus Infection in Kidney Transplant Recipients: Case Report

Chronic hepatitis C virus (HCV) infection exists in a large proportion of patients undergoing renal transplantation. Nowadays it is not considered to be an absolute contraindication to transplantation; however, it is associated with an increased risk for the patient and accounts for a shorter half-life of the renal allograft. We present three transplant recipients who displayed serious hepatic dysfunction after renal transplantation due to an HCV infection. In two of these cases, the liver biopsies established the diagnosis of FCH. In the third case, the liver biopsy was compatible with the early stages of FCH. All patients were started on peg-interferon alfa 2-b and ribavirin with subsequent normalization of hepatic function and early complete viral responses.

Specificity and Sensitivity of Screening for Anti-HLA Antibodies in Kidney Allograft Dysfunction

BACKGROUND: Prospective testing for posttransplant circulating anti-HLA antibodies seems to be a critical noninvasive tool, but confirmatory data are lacking. MATERIALS AND METHODS: Over the last 3 years, peritubular capillary (PTC) C4d deposition was prospectively sought by an immunofluorescence technique applied to frozen tissue in biopsies obtained for allograft dysfunction. Screening for circulating anti-HLA class I/II alloantibodies (AlloAb) by the flow cytometric test was performed simultaneously. RESULTS: We evaluated 132 sets of biopsies and simultaneous serum samples. PTC C4d deposition was demonstrated in 15.9% (21/132) of biopsies. Circulating anti-HLA I/II AlloAb were detected in 25% (33/132) of serum samples. Employing receiver-operator characteristic (ROC) curves for all C4d-positive biopsies, screening for AlloAb showed a global specificity of 82% and sensitivity of 61.9%. When this analysis was restricted to biopsies obtained in the first month posttransplantation, the sensitivity increased to 81.8%, but the specificity decreased to 76.9%. After the first month posttransplantation, we observed sensitivity of 40.0% and a specificity of 86.4%. In the first month posttransplantation, all patients with a diagnosis of acute antibody-mediated rejection displayed circulating anti-HLA class I/II, but not always at the same time as the C4d-positive biopsy. CONCLUSIONS: In the first month posttransplantation, prospective monitoring of anti-HLA antibodies may be useful. The high sensitivity allows the identification of patients at risk, affording an earlier diagnosis of antibody-mediated rejection. After the first month, the test can be used to evaluate allograft dysfunction episodes, since positivity is highly suggestive of an antibody-mediated process.

Leukopenia in Kidney Transplant Patients with the Association of Valganciclovir and Mycophenolate Mofetil

Cytomegalovirus (CMV) is the most common viral infection after transplantation. Valganciclovir (VGC) is established for prophylaxis and treatment of CMV infections, but leukopenia which appears in 10% to 13% (severe in 4.9%) is the principal side effect. We have recently noted an increased incidence of leukopenia and severe neutropenia among our renal transplant patients and thought to identify the associated factors. We conducted a retrospective analysis of all kidney transplantations performed between January 2005 and December 2006. All patients received mycophenolate mofetil (MMF), tacrolimus, and steroids. VGC was used for targeted prophylaxis and preemptive therapy of CMV infection, with doses adjusted to renal function. Of the 64 patients undergoing renal transplantation 13 (20.3%) developed leukopenia within 3 +/- 2 months after transplantation with severe neutropenia in 5 (7.8%). All patients were on MMF and VGC (VGC 605 +/- 296 mg/d). Leukopenia was significantly associated with simultaneous liver-kidney transplantation and with second kidney transplantations (P < .01). The incidence of leukopenia was higher among patients under VGC since day 1 of transplantation (P = .008) with maximal incidence observed among patients prescribed 900 mg/d as opposed to those on lower doses (P < .01). There was no increase in CMV infection among patients with a low dose of VGC. No patient developed clinical CMV disease. In conclusion, VGC prophylaxis was associated with an increased frequency of leukopenia on MMF-tacrolimus treated patients or regimens. Low-dose VGC for CMV prophylaxis appeared to be as effective as high-dose treatment, and associated less frequently with leukopenia and neutropenia.

Zero-Time Kidney Histology Predicts Early Graft Function

Our purposes are to determine the impact of histological factors observed in zero-time biopsies on early post transplant kidney allograft function. We specifically want to compare the semi-quantitative Banff Classification of zero time biopsies with quantification of % cortical area fibrosis. Sixty three zero-time deceased donor allograft biopsies were retrospectively semiquantitatively scored using Banff classification. By adding the individual chronic parameters a Banff Chronic Sum (BCS) Score was generated. Percentage of cortical area Picro Sirius Red (%PSR) staining was assessed and calculated with a computer program. A negative linear regression between %PSR/ GFR at 3 year post-transplantation was established (Y=62.08 +-4.6412X; p=0.022). A significant negative correlation between arteriolar hyalinosis (rho=-0.375; p=0.005), chronic interstitial (rho=0.296; p=0.02) , chronic tubular ( rho=0.276; p=0.04) , chronic vascular (rho= -0.360;P=0.007), BCS (rho=-0.413; p=0.002) and GFR at 3 years were found. However, no correlation was found between % PSR, Ci, Ct or BCS. In multivariate linear regression the negative predictive factors of 3 years GFR were: BCS in histological model; donor kidney age, recipient age and black race in clinical model. The BCS seems a good and easy to perform tool, available to every pathologist, with significant predictive short-term value. The %PSR predicts short term kidney function in univariate study and involves extra-routine and expensive-time work. We think that %PSR must be regarded as a research instrument.

C4d Presence in Kidney Allograft Biopsy: Sensitivity and Specifity of Immunoperoxidase vs Immunofluorescence

OBJECTIVES: Evaluate the sensitivity/specificity of immunoperoxidase method in comparison with the standard immunofluorescence. MATERIAL AND METHODS: Retrospective review of 87 biopsies made for allograft dysfunction. Immunofluorescence (IF) was performed in frozen allograft biopsies using monoclonal antibody anti-C4d from Quidel®. The indirect immunoperoxidase (IP) technique was performed in paraffin-embebbed tissue with polyclonal antiserum from Serotec®. Biopsies were independently evaluated by two nephropathologist according Banff 2007 classification. RESULTS: By IF, peritubular C4d deposition were detected in 60 biopsies and absent in 27 biopsies. The evaluation of biopsy by IP was less precise due to the presence of background and unspecific staining. We find 13.8% (12/87) of false negative and Banff classification concordance in 79.3% (69/87) of cases (table1). The ROC curve study reveal a specificity of 100% and sensitivity of 80.0 % of IP method in relation to the gold standard (area under curve:0.900; 95% Confidence interval :0.817-0.954; p=0.0001). Banff Classification C4d Cases Immunofluorescence Immunoperoxidase n =87 Diffuse Negative 3 (3.4%) Focal Negative 9 (10.3%) Negative Negative 27 (31.0%) Diffuse Diffuse 33 (37.9%) Focal Focal 9 (10.3%) Diffuse Focal 6 (6.9%) CONCLUSION: The IP method presents a good specificity, but lesser sensitivity to C4d detection in allograft dysfunction. The evaluation is more difficult, requiring more experience of the observer than IF method. If frozen tissue is unavailable, the use of IP for C4d detection is acceptable.

Validação da Importância dos Critérios de Referenciação Propostos pela Direcção Geral de Saúde para Realização de Ecocardiografia Fetal

Introdução: A malformação congénita mais frequente é a cardíaca, afectando cerca de 5-8 recém-nascidos/mil nados vivos. Actualmente é possível obter um diagnóstico pré-natal destas anomalias através do ecocardiograma fetal (EcoF), porém, porque os recursos em Saúde são limitados, este exame deve ser pedido de acordo com os critérios estabelecidos pela Direcção Geral de Saúde (DGS). Objectivos: Avaliar a importância dos critérios de referenciação propostos pela DGS para detecção de anomalias cardíacas. Determinar as taxas de prevalência e mortalidade nos fetos com doença cardíaca. Material e Métodos: Revisão casuística de uma amostra de 733 fetos aos quais foi realizado EcoF em consulta de Cardiologia Pré-natal num centro terciário de Cardiologia Pediátrica, no período de 2006 a 2008. Foram avaliados dados demográficos, motivo de referenciação (MR), resultados da EcoF e evolução. Classificámos os MR em dois grupos: (I) concordantes com as indicações da DGS- causas major (familiar, materna, fetal) e causas minor (outras situações); (II) não concordantes. Resultados: Realizaram-se 871 EcoF a 705 grávidas. A mediana da idade materna foi de 32 anos (15-45 anos) e a média da idade gestacional foi de 26 semanas (±4 sem). O grupo I incluiu 89% das grávidas. Identificaram-se 52 fetos (7%) com anomalias cardíacas: 42 estruturais, 8 de ritmo e 2 derrames pericárdicos. Estas anomalias distribuíram-se da seguinte forma: grupo I - causa familiar (3), causa materna (3), causa fetal (39), causas minor (5) e no grupo II (2). Observou-se um maior número de anomalias cardíacas no grupo I (6,8% vs 0,3%) (p> 0.05), sobretudo nos fetos referenciados por causa fetal (p<0,05). Perderam-se no controlo evolutivo 10 casos positivos, realizaram-se 3 interrupções médicas da gravidez e ocorreram 3 mortes. Mantêm-se em seguimento na consulta de Cardiologia Pediátrica 11 casos positivos. Conclusões: Na maioria dos casos cumpriram-se os critérios de referenciação da DGS, no entanto não se observou uma diferença estatisticamente significativa na prevalência de anomalias cardíacas fetais nas grávidas com e sem factores de risco. A causa fetal foi a que melhor se correlacionou com a presença de anomalia cardíaca. A prevalência destas anomalias e a taxa de mortalidade aferida na amostra pode estar subestimada por perda de casos positivos no controlo evolutivo.

Sotalol no Tratamento da Taquicardia Fetal

A taquicardia fetal é uma situação rara, que, quando mantida coloca em risco a vida do feto. O modo de tratamento não é consensual, existindo várias modalidades farmacológicas. O objectivo deste estudo foi avaliar a eficácia e segurança do sotalol no tratamento de taquicardias fetais. Material e métodos: Estudo retrospectivo, com base nos registos de consulta e entrevista às mães dos fetos com taquicardia supraventricular, referenciados ao Serviço de Cardiologia Pediátrica do Hospital de Santa Marta, durante um período de dez anos. Resultados: Foram diagnosticados oito fetos com taquicardia supraventricular, dos quais seis foram tratados com sotalol. A idade média de gestação na apresentação foi de 30 semanas. Nenhum feto apresentava cardiopatia estrutural, em dois verificou-se hidropisia fetal e outro apresentou hidrocefalia. A taquicardia era supraventricular em todos, sendo em dois por flutter auricular. Em todos os casos, excepto um, houve conversão a ritmo sinusal, não se registando efeitos secundários nas mães nem mortalidade fetal. No período neonatal em três crianças foram registados episódios de taquicardia supraventricular paroxística. Conclusão: O sotalol mostrou-se seguro e eficaz no tratamento das taquicardias fetais, mas, dada a pequenez da amostra, outros estudos mais alargados são necessários para se tirarem conclusões válidas.

Diabetes e Gravidez. Experiência da Consulta de Medicina Materno-Fetal do Serviço de Obstetricia e Ginecologia do Hospital de Dona Estefânia

Os autores realizaram um estudo retrospectivo das 87 grávidas vigiadas na Consulta de Diabetes do Hospital de Dona Estefânia com diabetes pré-gestacional tipo 1 e 2 e diabetes gestacional, durante um período de 2 anos. Analisararn a idade das grávidas, raça, paridade, tipo de diabetes, patologia associ ada, antecedentes familiares de diabetes, idade gestacional em que foi feito o diagnóstico de diabetes, insulinoterapia, evolução da gravidez, idade gestacional na altura do parto, características do parto e dos recém-nascidos e controlo no pós parto. A maioria das grávidas inscritas na consulta tinha idade superior a 30 anos (76%). A diabetes gestacional foi o tipo de diabetes mais frequente na consulta, tendo ocorrido sobretudo no 3° trirnestre. A hipertensão arterial crónica foi a patologia associada dominante, complicando-se em cinco casos de pré-eclâmpsia.Para além da pré-eclâmpsia, outra das complicacções mais frequentes foi a infecçãoo urinária. A cesariana foi o tipo de parto mais frequente. As suas principais indicações foram a cesariana electiva, a pré-eclâmpsia agravada e a distoócia. A macrossomia fetal só ocorreu em 5 dos 60 partos, refletindo um bom controlo metabólico.

Restrição do Crescimento Fetal - Casuística de 4 Anos

Overview and aims: Fetal growth restriction (FGR) affects 15% of pregnancies and is associated with both increased perinatal and neonatal morbidity and mortality and long-term effects in adult life. Our aim was to describe cases and outcomes of FGR from a tertiary perinatal care centre and identify the predictors of neonatal morbidity and mortality. Study design: retrospective cohort. Population: pregnancies with early or late FGR caused by placental factors followed from 2006 to 2009 in a tertiary perinatal care centre. Methods: we collected data from clinical records on demographics, clinical history and fetal ultrasound parameters. Perinatal and neonatal outcomes were stratiied according to gestational age (above or below 28 weeks) and we used bivariate analysis to identify any associations with clinical and imaging indings. Results: we included 246 pregnancies; hypertension was the most prevalent maternal risk factor (16%). There were 15 cases of early FGR, 11 of which had cesarean delivery due to deterioration of fetal Doppler parameters. Outcomes in this group included one fetal and three neonatal deaths. Of 231 cases of late FGR, 64% were delivered early given a non-reassuring fetal status i.e. due to changes in Doppler evaluation or altered Manning biophysical proile. There were four cases of perinatal death in this group, three of which delivered at 28 weeks. Neonatal morbidity was associated with lower gestational age, lower birthweight and progressive placental dysfunction (p<0.01). Conclusion: there was an association between neonatal morbidity and gestational age, birthweight and Doppler deterioration, particularly for deliveries below 28 weeks. The assessment of vascular changes through Doppler analysis allows anticipation of fetal deterioration and is a helpful tool in deciding the optimum timing of delivery.

Morte Fetal Tardia: Aspectos Obstétricos

A morte fetal tardia constitui um desafio para todos os obstetras. Apesar de intervenções efectivas no diagnóstico e terapêutica de algumas patologias como a diabetes gestacional, a pré-eclâmpsia e a taxa de morte fetal tardia mantêm-se desde há uma década relativamente constante, contribuindo de uma forma significativa para a mortalidade perinatal. Neste artigo é efectuada uma revisão de alguns aspectos obstétricos, uma reflexão sobre o conhecimento actual do tema.

Mineral and Bone Disease (MBD) on a Kidney Transplant Patient

A 50-year-old post-menopausal recipient of a kidney allograft with bone pain, osteoporosis, persistent hypercalcaemia and elevated parathormone (PTH) levels, despite a satisfactory graft function, was treated with bisphosphonates and cinacalcet starting, respectively, 5 and 6 months after renal transplantation (RT). Sixteen months after treatment, there was improvement of bone mineral density (BMD) measured by dualenergy X-ray absorptiometry (DEXA). A bone biopsy was taken, unveiling a surprising and worrisome result. Post-RT bone disease is different from classic CKD-MBD and should be managed distinctly, including, in some difficult cases, an invasive evaluation through the performance of a bone biopsy, as suggested in the KDIGO guidelines.